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Abstract
Background: Accurate and reliable laboratory methods are needed for estimation of HIV-1 incidence to identify the high-
risk populations and target and monitor prevention efforts. We previously described a single-well limiting-antigen avidity
enzyme immunoassay (LAg-Avidity EIA) to detect recent HIV-1 infection.
Methods: We describe here further optimization and characterization of LAg-Avidity EIA, comparing it to the BED assay and
a two-well avidity-index (AI) EIA. Specimen sets included longitudinal sera (n=393), collected from 89 seroconverting
individuals from 4 cohorts representing 4 HIV-1 subtypes, and sera from AIDS patients (n=488) with or without TB co-
infections from 3 different cohorts. Ninety seven HIV-1 positive specimens were purchased commercially. The BED assay,
LAg-Avidity EIA, AI-EIA and HIV serology were performed, as needed.
Results: Monitoring quality control specimens indicated high reproducibility of the LAg-Avidity EIA with coefficient of
variation of ,10% in the dynamic range. The LAg-Avidity EIA has an overall mean duration of recency (v) of 141 days (95%
CI 119–160) at normalized optical density (ODn) cutoff of 1.0, with similar v in different HIV-1 subtypes and populations (132
to 143 days). Antibody avidity kinetics were similar among individuals and subtypes by both the LAg-Avidity EIA and AI-EIA
compared to the HIV-IgG levels measured by the BED assay. The false recent rate among individuals with AIDS was 0.2%
with the LAg-Avidity EIA, compared to 2.9% with the BED assay. Western blot profiles of specimens with increasing avidity
confirm accurate detection of recent HIV-1 infections.
Conclusions: These data demonstrate that the LAg-Avidity EIA is a promising assay with consistent v in different
populations and subtypes. The assay should be very useful for 1) estimating HIV-1 incidence in cross-sectional specimens as
part of HIV surveillance, 2) identifying risk factors for recent infections, 3) measuring impact of prevention programs, and 4)
studying avidity maturation during vaccine trials.
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Introduction
In the last decade, significant national and international efforts
have focused on HIV prevention, care, and treatment of HIV-
infected individuals in many countries. Major international
initiatives such as the President’s Emergency Plan for AIDS Relief
(PEPFAR) aims to prevent 12 million new infections. Recent focus
on combination prevention is also geared towards reducing new
transmissions. Although major strides have been made on several
fronts, measuring the impact of these scaled up programs on HIV
incidence has remained challenging.
The burden of the HIV epidemic is routinely measured by
prevalence, the proportion of individuals with HIV. However,
monitoring emerging epidemics in subpopulations, such as those
most at risk for infection, are not apparent in these numbers [1].
The measurement of incidence can elucidate transmission
dynamics of new HIV infections and allow tracking of epidemi-
ological trends. Additionally, incidence measurements can help
target prevention programs and determine the effectiveness of
these programs in reducing HIV infections. However, develop-
ment of a reliable method to estimate HIV-1 incidence has
remained elusive [2,3].
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modeling can be used to derive HIV-1 incidence estimates, there
are limitations to these approaches that include: the complexities
of following a cohort of individuals at risk for acquiring HIV
infection, such as high costs, recruitment bias, and the Hawthorne
effect where participants modify their behavior after enrollment in
the study, and biases in the assumptions that lead to inaccuracy for
modeled-based estimates. Therefore, laboratory-based methods
for incidence estimation have continued to be attractive due to the
simplicity, ease of testing, low cost and application to single cross-
sectional specimens collected during routine surveys. Laboratory
assays were developed and applied to detect acute and recent
HIV-1 infection for the purpose of estimating HIV-1 incidence
starting in the mid-1990s [4,5,6,7,8,9,10,11,12]. Diagnosis of acute
infection relies on the detection of p24 antigen or RNA prior to
elicitation of HIV antibodies. However, acute detection methods
are not ideal for incidence estimation because of the short duration
of the RNA/p24 detection period and consequent impact of the
variability of the ‘‘mean acute period’’ [12]. A change of one to
two weeks in the mean acute period could significantly alter the
precision of incidence estimates because of the short duration of
the acute phase. Moreover, this approach requires testing of a
large number of HIV negative individuals, which can be very
expensive and is not practical for resource-constrained settings.
Since 1998, the focus of laboratory-based methods has been to
detect recent seroconversions among HIV-1 antibody positive
individuals based on maturation of evolving antibodies that usually
follows a predictable pattern. Earlier efforts were focused on
development of methods, such as less-sensitive EIAs or the BED-
capture EIA (BED-CEIA), to quantify parameters, such as
antibody titer [4,9] or indirect measurements of HIV antibodies
levels [6,13], for the purpose of recent or long-term classification.
Currently, the BED assay is the only commercial assay developed
specifically for incidence surveillance and is used widely for
incidence estimation and characterization of recent infections
[14,15,16,17,18,19]. Additional studies have demonstrated limita-
tions of these approaches due to HIV-1 subtype variations, as in
the case of modified commercial assays [20,21], or due to
population differences, as in the case of BED assay [22].
Therefore, novel and more robust laboratory tools that go beyond
current methods are needed to estimate HIV-1 incidence.
Recent efforts around incidence estimation are focused on
measurement of antibody avidity, which increases over time
following seroconversion. Antibody avidity is believed to be more
robust than antibody titer because it is a functional property of
maturing antibodies [23]. Most descriptions of avidity measure-
ments utilize commercial HIV diagnostic assays [7,10,24] that are
modified to measure avidity index. Avidity is commonly expressed
as an ‘‘avidity index (AI),’’ a ratio of optical density (OD) values
from a two-well assay, where one well is treated with a chaotropic
reagent to dissociate low-avidity antibodies and a second untreated
well is used as a control. However, commercial assays are likely to
have subtype-dependent performance [20,21]. In addition,
commercial diagnostic assays include multiple antigens with
several different epitopes that elicit antibodies with varying
timeline and maturation kinetics, further complicating avidity
measurements [23]. We recently described two novel assays,
including a two-well avidity index EIA (AI-EIA) and a single-well
limiting antigen avidity EIA (LAg-Avidity EIA), to measure avidity
of HIV antibodies [25]. Key features of the one-well assay are: 1)
use of rIDR-M, a multi-subtype recombinant protein that covers
the immunodominant region (IDR) of gp41 of HIV-1, group M, 2)
the limiting amount of antigen available to allow binding of only
high-avidity antibodies, and 3) use of pH 3.0 buffer to further
assist dissociation of low avidity antibodies. We have now further
optimized and characterized the assay; this report describes
performance characteristics of the assay in different populations
and HIV-1 subtypes, demonstrating that the assay has similar
performance among individuals infected with different subtypes
and across different populations and may be an important tool for
measurement of HIV-1 incidence worldwide.
Materials and Methods
Longitudinal specimens from incident infections
Available longitudinal specimens (n=393) from 89 serocon-
verting individuals, collected as part of 4 different cohorts from
Amsterdam (subtype B, N[# of subjects]=25, n[# of speci-
mens]=100), Trinidad [subtype B, N=7, n=71], Kenya
[subtype A and D, N=34, n=81] and Ethiopia [subtype C,
N=23, n=144], were tested with the three incidence assays (BED
assay, LAg-Avidity EIA and AI-EIA). These specimens were
obtained from various collaborators and collected as part of
different longitudinal cohort studies; they were also used recently
to determine the mean duration of recency for the BED assay [22].
The mid-point of last negative date and first positive date was used
to infer the time of seroconversion and used to calculate time since
seroconversion for subsequent positive specimens.
Cross-sectional HIV-1 positive specimens
A total of 97 HIV-1 positive plasma specimens were purchased
from Boca Biolistics, Inc. (Coconut Creek, FL) and used for the
development of controls and calibrator (CAL), optimization of the
LAg-Avidity EIA, and as a cross-sectional specimen set for testing.
These bulk volume specimens (,200 mL each) were thoroughly
characterized with respect to HIV serology testing and HIV-1
Western blot assay.
Specimens from individuals with AIDS
Specimens from individuals (N=488) with AIDS (CD4,200)
were derived from three sources and used to estimate a false recent
rate for the LAg-Avidity EIA. Two hundred and sixty one
specimens (n=261) were collected in the 1990s from treatment-
naı ¨ve women with AIDS enrolled in the HIV Epidemiologic
Research Study (HERS) [26]. Additional specimens were from
Thailand (n=128) and Cote d’Ivoire (n=99), collected in the
1990s from treatment-naı ¨ve AIDS patients with (Cote d’Ivoire) or
without (Thailand) tuberculosis (TB).
LAg-Avidity EIA
The design and development of the rIDR-M recombinant
protein was previously described [25,27]. A large batch of rIDR-
M was commercially made for coating consistency (Proteos,
Kalamazoo, MI); results presented here were obtained using plates
coated with this large batch of rIDR-M. The protein was dissolved
in dimethyl sulfoxide at a high concentration of 5 mg/mL,
aliquoted and stored frozen at 280uC. Nunc MaxiSorp 96-well
microplates (Thermo Scientific, Rochester, NY) were coated with
0.063 mg/ml of rIDR-M which was determined to be the optimal
antigen concentration for the assay. Each well was coated with
100 mL of freshly prepared 0.063 mg/mL rIDR-M in cold 0.1 M
phosphate buffer solution (PBS), pH 7.4 containing 0.1% sodium
azide (Sigma Aldrich, St. Louis, MO) that was 0.2 mM-filtered
prior to use. The plates were incubated overnight at 4uC, then
washed two times with 300 mL/well of PBS containing 0.1%
Triton X-100 (Sigma Aldrich) (PBS-Triton). Plates were blocked
with 200 mL of 5% nonfat dry milk powder (Nestle Carnation,
Wilkes-Barre, PA) in PBS-Triton (milk buffer) for 1 hr at 37uC and
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plates were dried at 37uC for 1 hr, covered with a plate sealer, and
stored frozen with desiccant in ZiplocH bags at 230uC until use.
To perform the assay, all the reagents were allowed to come
to room temperature before use, except the TMB substrate,
which was placed in the 25uC incubator for up to 8 hours until
use, and the goat anti-human IgG peroxidase, which was kept at
220uC until use. Specimens, controls, and CAL were diluted
1:101 in milk buffer and 100 mL of the diluted specimens or
controls were added to their respective well and incubated for
1h ra t3 7 uC. Plates were washed four times with 300 mlo fP B S -
Triton buffer (wash buffer), and then 200 mL/well of dissociation
buffer (citrate buffer, pH 3.0, TEKnova, Hollister, CA) was
added and incubated for 15 min at 37uC. The plates were
washed and 100 mL of a 1:5000 dilution of goat-antihuman IgG
peroxidase (KPL, Gaithersburg, MD) in milk buffer was added
to each well and incubated for 30 min at 37uC. The plates were
washed again and incubated with 100 mL/well of TMB substrate
(KPL) for 15 min at 25uC. The reaction was stopped by the
addition of 100 mL/well of 1 N H2SO4 (Sigma Aldrich) and the
optical density (OD) was read at 450 nm. Normalized OD
(ODn) values were calculated for each specimen using a CAL
specimen tested on the same plate as follows: ODn=specimen
OD/median CAL OD. All controls and CAL specimens were
tested in triplicate, diluted individually, and median values were
used. All other specimens were tested in singlet but on two
separate runs to generate duplicate values and to account for
inter-run variations. Mean ODn values of two runs were used
for further analysis.
Two-well avidity-index EIA (AI-EIA)
Micro-well plates were coated with 0.125 mg/ml of purified
rIDR-M, using the same coating steps as the one-well assay. HIV-
1 positive specimens and controls, diluted 1:101 in milk buffer,
were incubated in duplicate wells for 1 hr at 37uC. After the
antibody was bound, the plates were washed four times with
300 ml wash buffer, and then one well was incubated for
15 minutes with 0.1 M dissociation buffer (citrate buffer,
pH 3.0, treated well), while the other well was incubated with
wash buffer (control well). The plates were washed and 100 mLo f
a 1:5000 dilution of goat-antihuman IgG peroxidase (KPL,
Gaithersburg, MD) in milk buffer was added to each well and
incubated for 30 min at 37uC. The plates were washed again and
incubated with 100 mL/well of TMB substrate (KPL) for 15 min
at 25uC. The reaction was stopped by the addition of 100 mL/well
of 1 N H2SO4 (Sigma Aldrich) and the optical density (OD) was
read at 450 nm. The AI for each specimen was calculated
as=(OD of treated well/OD of control well)6100. All specimens
were tested on two separate runs to generate two values and the
mean AI was used for further data analysis.
HIV-1 BED Incidence EIA (BED assay)
The assay has been previously described in detail [6,13] and was
performed according to the manufacturer’s instructions. The data
for specimens used in this study were generated earlier and
represent a subset of specimens reported [22].
HIV Serology
Genetic Systems HIV-1-2 Plus O EIA (Bio-Rad Laboratories,
Hercules, CA) was performed according to the manufacturer’s
instructions. The Cambridge Biotech HIV-1 Western Blot
(Maxim Biomedical, Rockville, MD) was performed as per kit
instructions.
Determination of the mean duration of recency
The mean duration of recency was derived from longitudinal
specimens of seroconverting individuals representing 3 different
HIV-1 subtypes and also for overall for all seroconverters
combined. The statistical method used to calculate the mean
duration of recency has been described recently [22]. Here, a
similar but a more general approach was followed. In brief, a
nonparametric survival analysis method for interval-censored data
was used to estimate the recency period of the assay. This
approach required fewer assumptions than other approaches. It
was adapted in our context where it was known that seroconver-
sion had occurred between two time points, t1 and t2, and assay
threshold was crossed between time points, t3 and t4. Therefore
the recency period lies in the interval (t3 -t 2) and (t4 -t 1). If the
threshold was not crossed by the last observation then the upper
end of this interval was set as censored. These two limits were used
to calculate the maximum likelihood estimate of the survival curve.
The mean and median estimates of the recency period were
directly derived from the survival curve. For the mean to be
defined finitely, it was assumed that the event occurred for the
longest observed subject at the latest observed time. We employed
a SAS macro called EMICM to estimate the survival curve for the
recency period [28]. Confidence intervals were estimated based on
bootstrap techniques. Upper and lower limits of the interval were
derived as 97.5
th and 2.5
th percentiles of the empirical distribution.
We used various threshold values and derived estimates for each of
the subtypes and overall recency period.
Results
LAg-Avidity EIA Controls
Selected bulk volume HIV-1 positive specimens with OD in the
dynamic range were chosen as low positive control (LPC),
calibrator (CAL), and high positive control (HPC). The controls
and CAL were undiluted plasma specimens. CAL was chosen such
that its OD value was between 0.6–0.8, with HPC and LPC
bracketing the CAL. A summary of their raw OD values and
normalized OD values (ODn) from 94 plate runs from three
different plate lots are shown in Table 1. By definition, CAL has
an ODn of 1.0 while LPC and HPC were selected to have ODn of
approximately 0.5 and 1.5–1.6, respectively. Coefficient of
variation for LPC, CAL and HPC were .20% for raw OD
values (Table 1) but decreased to ,10% for ODn values,
demonstrating that normalization of OD value for each specimen
is important for reducing inter-run variations.
Table 1. Mean OD and ODn values for CAL and controls,
including standard deviation (SD) and coefficient of variation
(%CV) from 94 runs.
Control ID Raw OD values ODn Values
Mean OD+SD %CV Mean ODn+SD %CV
NC 0.08960.016 17.5 0.15160.044 29.5
CAL 0.62460.151 24.3 1.000 0.0
LPC 0.30560.067 21.9 0.49560.047 9.5
HPC 0.99660.223 22.4 1.60960.124 7.7
NC-negative control, CAL=calibrator, LPC=low positive control and HPC=high
positive control specimens.
doi:10.1371/journal.pone.0033328.t001
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different subtypes
LAg-Avidity EIA results of specimens from 4 longitudinal
cohorts, representing 3 different subtypes, are shown in Figure 1.
Antibody avidity, as measured by LAg-Avidity EIA, increased in
almost all cases over time. Specimens from individuals infected
with subtype B (Amsterdam and Trinidad cohorts) were more
uniformly spaced with frequent and regular sampling, thus
providing a coherent picture of avidity kinetics. In contrast, some
individuals infected with subtype A or D (Kenya cohort) or
subtype C (Ethiopia cohort) had large inter-sample interval with
an irregular sample collection schedule, which was reflected in
more heterogeneity of kinetics. It should be noted that the scale is
different in the last panel (subtype C) because of longer follow up
of these individuals.
Comparison of BED, LAg-Avidity EIA and Avidity-Index
EIA in Seroconverters
Compiled antibody kinetics data for all 89 seroconverters for
BED, LAg-Avidity EIA and two-well rIDR-M AI-EIA are shown
in Figure 2. All plots have the same scales on the X-axes for ease of
comparison. For the BED assay, most individuals show an increase
in HIV antibody levels over time. However, there is more
heterogeneity among individual responses, including some which
ramp up slowly or even decline over time and go below the cutoff
of 0.8 ODn, contributing to the misclassification as recent
infection. In contrast, both one-well and two-well avidity assay
kinetics were rapid, with less variation among individuals
compared to the BED assay. Interestingly, both one-well LAg-
Avidity EIA and two-well AI-EIA had similar performance, and
none of the individuals tested stayed below the proposed cutoff of
1.0 ODn for LAg-Avidity EIA or the matching cutoff of 40%
avidity index for AI-EIA. All subsequent work described here is
focused on LAg-Avidity EIA.
Mean Duration of Recency
Mean duration of recency (v) at varying cutoff for LAg-Avidity
EIA was calculated using the non-parametric survival method for
interval estimation described earlier [22]. Figure 3A shows the
relationship between cutoff value and v, where the value of v was
100 days (95% CI 81–122) at 0.5 ODn cutoff and increased to 216
days (95% CI 182–258) at cutoff of 2.0 ODn. At cutoff of 1.0
ODn, the v value was 141 days (95% CI 119–160). Further
analysis was performed using an assay cutoff of 1.0 ODn which
should have the least variability due to normalization. The
empirical frequency distribution of duration of recency is shown in
Figure 3B, which demonstrates that v has approximately normal
distribution with a peak at about 140 days.
Subtype specific analysis, summarized in Table 2, demonstrated
that the v was very similar across the different subtypes and
ranged from 132 days (subtype B) to 143 days (subtype C), with
significant overlap of confidence intervals (all p-values for pair-wise
tests exceed 0.5). This suggests that the LAg-Avidity EIA has
similar performance in these cohorts representing 4 different HIV-
1 subtypes.
Misclassification among people with AIDS
Overall, the BED assay misclassified 14 (2.9%; 95% CI 1.4%–
4.4%) of 488 individuals with AIDS (with or without TB) as having
recent infections (Table 3). The misclassification varied from 0.8%
(95% CI 0.0%–2.23%) in Thailand specimens to 4.2% (95% CI
1.8%–6.6%) in HERS specimens. In comparison, misclassification
with LAg-Avidity EIA was 0.2% (95% CI 0.0%–0.6%) with only 1
of the total 488 individuals being misclassified as having recent
infection.
Application to a cross-sectional specimen set
As a proof of concept, we applied this assay to 97 HIV-1 positive
specimens purchased from a commercial source (see Methods).
Figure 1. Antibody avidity maturation post-seroconversion as measured by LAg-Avidity EIA in individuals from 4 cohorts
representing different geographic locations and subtype infections: Amsterdam and Trinidad cohorts (subtype B; left), Kenya
cohort (subtypes A and D; middle), and Ethiopia cohort (subtype C; right). Each line represents a single individual with sequential
specimens collected over time post-seroconversion (X-axis; note that scale is different in panel C due to longer follow up).
doi:10.1371/journal.pone.0033328.g001
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33328Figure 2. Comparative HIV antibody kinetics following seroconversion as detected by the BED assay (left), LAg-Avidity EIA
(middle), and Avidity Index-EIA (right) among 89 seroconverting individuals (subtypes A ,B, C & D). The BED assay measures increasing
proportion of HIV-specific IgG in total IgG, while LAg-Avidity EIA and AI-EIA measure increasing avidity of HIV antibody. Both LAg-Avidity EIA and AI-
EIA use multi-subtype gp41 recombinant protein, rIDR-M, and pH 3.0 dissociation buffer to distinguish recent and long-term HIV infections.
doi:10.1371/journal.pone.0033328.g002
Figure 3. A) Increase in duration of mean recency (solid line) of LAg-Avidity EIA with varying cutoffs from 0.5 to 2.0 ODn. The 95%
confidence interval is shown by dotted lines. The numbers shown represent mean duration of recency, v, at each cutoff. B) Empirical frequency
distribution of duration of recency at cutoff of 1.0 for LAg-Avidity EIA.
doi:10.1371/journal.pone.0033328.g003
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specimen set and all, except one, were strongly positive on
diagnostic Bio-Rad HIV-1-2-O assay with OD value of 4.0 (the
upper limit of the reader). One specimen had a low OD value of 0.
510 but was repeatedly positive (above the cutoff) on the diagnostic
EIA (Figure 4A). The specimens had varying avidity as measured
by LAg-Avidity EIA with 14 specimens being classified as recent
infections (ODn#1.0). The specimens were arranged in ascending
order of avidity to represent imputed increasing time from
seroconversion (Figure 4A) and were tested with the HIV-1
Western blot assay (Figure 4B). For simplicity, results of only the
first 35 individuals with the lowest LAg-Avidity assay reactivity are
shown (panel A), along with corresponding Western blot results for
the first 32 individuals (panel B). Although these are single
specimens from different individuals, when arranged in the order
of increasing avidity, the WB banding pattern showed increased
number and intensity of bands representing maturation of HIV
antibodies that are typical of a seroconverting individual. The first
14 specimens are classified as recent by the LAg-Avidity EIA
(demarcation shown by an arrow) and have weaker/partial
banding patterns. Subsequent specimens are classified as long-
term infection with only 19 shown here for simplicity. The WB
banding patterns were typical of long-term infections with strong
antibodies to most HIV proteins. All the rest had full WB banding
patterns. Of particular interest is specimen ID 27 that has strong
antibodies to envelope proteins but weak anti-gag (p24) antibodies,
typical of individuals with advanced disease. Specimens such as
these are more often misclassified as recent with the BED assay,
but they are correctly identified as long-term infections with the
LAg-Avidity EIA.
Discussion
Intensive efforts by national HIV control programs of many
countries, with support from several global initiatives, such as
PEPFAR and the Global Fund to Fight AIDs, TB, and Malaria,
have made significant impact on transmission of HIV infection
[16,29]. UNAIDS recently reported .25% reduction in HIV
incidence in 33 countries [30], with 22 of them in sub-Saharan
Africa, and HIV incidence appears to have stabilized or is showing
signs of decline in 5 of the most affected countries. However, the
model-based incidence estimates are retrospective and not as
timely as needed for targeting prevention efforts and allocation of
resources. Moreover, the estimates depend on several assumptions
and do not lend themselves to sub-population estimates and risk-
factor analyses that are so crucial for targeting interventions.
Therefore, laboratory-based methods applied to cross-sectional
samples continue to remain attractive, with the potential to
provide information on current transmission dynamics and hot-
spots [2].
We previously described development of a novel single-well
avidity assay (LAg-Avidity EIA) and a two-well avidity index assay
(AI-EIA), both using a multi-subtype recombinant gp41 protein
(rIDR-M), to detect recent HIV-1 infections in cross-sectional
specimen sets [25]. We extend this study to demonstrate that the
LAg-Avidity EIA can detect and distinguish recent and long-term
infections with high accuracy and has similar performance in 4
divergent subtypes tested. The novel features of LAg-Avidity EIA
are: 1) the ability to measure antibody avidity in a single well
simply by limiting the amount of antigen available to bind the
antibodies, 2) the use of a multi-subtype gp41 recombinant
protein, which reduces or eliminates bias among different subtypes
or population, resulting in similar duration of recency, 3) the use of
a low pH buffer (pH 3.0) to facilitate the differentiation between
recent and long-term infection, and 4) the improved reproduc-
ibility and increased number of specimens that can be tested per
plate due to the single well format for measuring antibody avidity.
Avidity maturation kinetics were very similar by both 1-well LAg-
Avidity EIA and 2-well AI-EIA, indicating that this new approach
measures antibody avidity but in a single-well (Figure 2).
Currently, the BED assay is the only assay commercially
available specifically to measure HIV-1 incidence in cross-
sectional populations and is used in more than 50 laboratories
worldwide [18,31,32,33]. The assay has high precision [34],
although its accuracy to detect recent infection has been
questioned due to false recent classification resulting in elevated
incidence estimates [31,35,36,37]. Moreover, recent analysis
demonstrated that the assay has a significantly higher mean
duration of recency in African populations than in other
populations [22]. Both these limitations appear to result from
the capture format of the assay, which captures both HIV-1 IgG
and non-HIV-1 IgG, to determine the proportion of HIV-1 IgG;
Table 2. Summary of mean recency period (in days) for LAg-Avidity EIA at cutoff of 1.0 by cohort and prevalent HIV-1 subtype(s).
Cohort
No. of Subjects (No. of
specimens) HIV-1 Subtypes
Mean Recency Period
(95% CI), in Days
Amsterdam & Trinidad 32 (170) B 132 (104–157)
Ethiopia 23 (143) C 139 (106–178)
Kenya 34 (80) A, D 143 (103–188)
ALL 89 (393) A, B, C and D 141 (119–160)
doi:10.1371/journal.pone.0033328.t002
Table 3. Frequency of false recent classification and false
recent rates (FRR) for the BED and LAg-Avidity EIA in
specimens collected from individuals with AIDS and AIDS with
TB co-infections.
Frequency of False Recent
Classification (%)
Cohort BED-CEIA LAg-Avidity EIA
US, AIDS (n=261) 11 (4.2%) 0 (0.0%)
Thailand, AIDS+TB (n=128) 1 (0.8%) 0 (0.0%)
Cote d’Ivoire , AIDS+TB (n=99) 2 (2.0%) 1 (1.0%)
OVERALL (n=488) 14 (2.9%) 1 (0.2%)
doi:10.1371/journal.pone.0033328.t003
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bias [22].
Development of a new generation of avidity assays, described in
our recent work [25], was geared to address these limitations and
those that may impact modified commercial assays. We developed
a multi-subtype gp41 recombinant protein and used it in two
different avidity assays, including the novel single-well format. We
also describe development of control specimens, including CAL
which is important for normalization of OD values to reduce inter-
run variations and determination of the assay cutoff. The HPC
and LPC were developed to bracket the CAL in the dynamic
range. Monitoring values of controls over .90 plates demonstrat-
ed that calculation of ODn improves consistency and reduces
coefficient of variation to ,10%, especially in the dynamic range
that is important for classification of recent and long-term
infection (Table 1).
We demonstrate here that the LAg-Avidity EIA has a similar
mean duration of recency among 2 cohorts from Africa (Kenya,
representing subtype A &D, and Ethiopia, representing subtype C)
and 2 additional cohorts from Amsterdam and Trinidad,
representing subtype B (Table 2). Overall, the mean duration of
recency or v increased from 100 days at a cutoff of 0.5 ODn to
216 days at 2.0 ODn (Figure 3A). A cutoff of 1.0 ODn corresponds
to v of 141 days (95% CI 119–160) and was chosen for application
in cross-sectional settings because the CV is the lowest close to the
CAL specimen and the duration of recency period is between 4
and 5 months, which is sufficiently long to detect new infections for
good incidence estimates. Subtype-specific analysis show that
window periods are similar and range from 131 to 143 days
(Table 2). Two subtypes, A & D from Kenya, were analyzed
together due to a limited number of samples available to perform
statistically sound calculation of v for each subtype. However, the
pattern of avidity kinetics were very tight, irrespective of HIV-1
subtypes (Figure 1 & 2), with uniform distribution of recency
periods (Figure 3B), indicating that v values for 4 subtypes are
quite similar. Similar analysis of the BED window period recently
showed a non-normal distribution with a right tail, although these
results were derived from much larger data set [22]. Additional
work with more longitudinal specimens, representing different
populations and subtypes, will be required to further refine our
findings. However, it is important to note that v values are also
affected by precision of seroconversion time as determined by
collection interval between last negative and first positive samples
and frequency of sample collection from seroconverting individ-
uals. Therefore, it is expected that v will be revised as more
seroconverters are tested as part of ongoing calibration of new
incidence assays by us and other laboratories as the assay becomes
widely available.
It was very encouraging that the misclassification rate among
488 individuals with AIDS was only 0.2% (1 of 488) for the LAg-
Avidity EIA, compared to 2.9% (14 of 488) with the BED assay.
Additional testing of specimens from two different ART-naı ¨ve
populations with documented long-term infections (.1 year) also
suggest low false recent classification rate (FRR) (data to be
published separately), which is consistent with characteristics of an
acceptable assay to provide accurate incidence estimates [38]. This
suggests that the LAg-Avidity assay is likely to perform better
among those with long-term infections, including AIDS; however,
Figure 4. A) Comparative OD or ODn values of a cross-sectional specimen set tested with Genetics Systems HIV-1/HIV-2 Plus O EIA
and LAg-Avidity EIA. Specimens are arranged in ascending ODn on LAg-Avidity EIA to represent avidity maturation since seroconversion; a
horizintal line at 1.0 indicates cut-off for recent and long-term classification. Only first 35 specimens are shown for clarity. B) Corresponding HIV-1
Western blot banding profile of first 32 specimens showing increase in number and intensity of bands typical of antibody maturation. For the
purpose of incidence estimation, vertical arrow indicates cutoff; recent infections=left of the arrow, long-term infections=right of the arrow.
doi:10.1371/journal.pone.0033328.g004
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and state of the epidemic before this determination can be made
definitively.
Both less-sensitive EIAs and the BED assay show increased
‘‘misclassification’’ when individuals are on anti-retroviral treat-
ment (ART) or are elite suppressors with low viral load [39,40,41].
With expanded treatment programs in most countries, this could
have significant impact on incidence estimates unless that
information is collected during the survey. In a limited study of
individuals on ART, the LAg-Avidity EIA performed better than
the BED assay (unpublished data); however, a larger sample size
and information on duration of treatment are needed before we
can quantify the impact of ART. If misclassification among people
on ART continues to be a significant factor by antibody-based
assays, use of another assay based on a different principle or
detection of ARV in samples classified as recent should be
considered which can improve the incidence estimate [17]. It is to
be noted that the latter exercise needs to be conducted only on
samples that are classified as recent, limiting the cost of additional
testing for ARV.
As in diagnostic assays, two or more tests based on different
principles (e.g., BED and avidity assay) can be used in an
algorithm (parallel or serial) to increase the predictive value of
detecting recent seroconversion and to exclude false recent
misclassifications. In addition, further testing for CD4, viral load
and ARV have been proposed to improve the estimates. However,
there must be demonstrated contribution and advantages of each
of the steps/assays for improved incidence estimates. Otherwise,
increased cost of performing multiple assays will not be
worthwhile. Additional testing of cross-sectional specimen sets
with the BED and LAg-Avidity assays, as well as other incidence
assays, will help in formulating a definitive guidance about the
utility of multi-assay algorithm, if any.
Often, and incorrectly so, the incidence assays are characterized
for sensitivity and specificity to detect recent HIV infection.
Although long-term specificity of the assay is important among
those infected .1 year, sensitivity and specificity are not relevant
for detecting and distinguishing recent from long-term infections
during the early phase of infection since the mean duration of
recency is applicable only to populations, not to individuals.
Accordingly, the mean recency period of 141 days is meant for
incidence estimate calculation only. However, data from the
frequency distribution of recency period (Figure 3B) indicate that
those below cutoff of 1.0 are very likely to have seroconverted
within the last 180 days with high probability; hence, such data
may be useful for research and public health applications at the
individual subject level, specifically for the prevention purposes,
transmission of drug-resistance viruses and similar studies.
With development of controls, CAL and other key reagents, this
novel LAg-Avidity assay is now well-standardized. Our application
in a cross-sectional specimen set suggest that the assay detects
recent HIV-1 infection with high accuracy and that an increase in
ODn reflects avidity maturation of HIV antibodies following
seroconversion, as confirmed by evolving Western blot banding
pattern (Figure 4). As part of the World Health Organization
(WHO) Incidence Working Group, we are planning additional
independent multi-center evaluations of the LAg-Avidity EIA for
detecting recent infections.
HIV vaccine developmental work has lately focused on
elicitation of high avidity antibody as a marker for effective
humoral response and possibly as a surrogate for protection
[42,43]. Multiple versions of avidity assays are in use to evaluate
the vaccine response; however these avidity assays are difficult to
compare or to transfer from one laboratory to another due to lack
of standardization and appropriate quality controls. Moreover,
most assays use antigens derived from subtype B or those used for
a specific candidate vaccine. The standardized avidity assay
described here may also have applications for studying antibody
maturation in vaccine recipients if gp41 antibodies are elicited,
irrespective of the subtype-specific vaccine. This assay can also be
used to evaluate antibody maturation in HIV-infected individuals
following break-through infections. This new concept of simply
limiting the antigen to measure antibody avidity, all in a single
well, can also be extended to other antigens and pathogens where
2-well avidity index based assays are routinely used.
We realize that in-house incidence assays will not be used widely
unless they are produced and are available commercially, as has
been the limitation for some of the other in-house assays described
earlier [11,44]. Therefore, development of a commercial kit is an
important step towards wider availability and application.
Recently, we have transferred the technology to commercial
companies and expect availability of a kit(s) in the near future
which will further facilitate additional validation and use of the
test.
In summary, the need for a reliable laboratory method to
estimate HIV-1 incidence from cross-sectional specimen sets
cannot be overemphasized. Such a tool can help maximize
impact of our efforts to reduce new HIV infections by zeroing in
on hot-spots and permitting the best use of scarce resources. This
novel single-well avidity assay has performance characteristic
suitable for detecting recent HIV-1 infection with high accuracy in
divergent subtypes or populations and should provide a reliable
laboratory tool to estimate HIV-1 incidence worldwide.
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